V

    Verrica Pharmaceuticals Inc (VRCA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.46
    -0.23 (-4.04%)

    Market Cap: $97.75M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(20/33)
    Avg Surprise
    +13.15%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.54
    Range$-0.57 - $-0.50
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.43+20.5%
    30d ago$-0.43+20.5%
    7d ago$-0.43+20.5%
    Current$-0.54
    Revenue Consensus
    $6M
    Range$5M - $8M
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.46 - $-0.35
    3 analysts
    Revenue Consensus
    $8M
    Range$6M - $10M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.41---
    Sep 26EST
    		-$-0.54---
    Jun 26
    		$-0.54$-0.47-14.89%Miss-316.0%
    Mar 26
    		$-0.45$-0.59+22.98%Beat+54.6%
    Dec 25
    		$-0.51$-0.64+20.31%Beat-153.4%
    Sep 25
    		$-0.03$-0.06+50.00%Beat+99.4%
    Jun 25
    		$0.25N/A+130.12%Beat+106.8%
    Mar 25
    		$-1.00$-1.36+26.47%Beat+77.3%
    Dec 24
    		$-0.20$-0.24+16.82%Beat+62.0%
    Sep 24
    		$-4.90$-3.87-26.61%Miss+9.3%
    Jun 24
    		$-3.70$-4.02+7.96%Beat-54.2%
    Mar 24
    		$-4.40$-4.40+0.00%Beat-193.3%
    Dec 23
    		$-0.53$-0.53+0.00%Beat-278.6%
    Sep 23
    		$-5.40$-3.90-38.46%Miss-1688.2%
    Jun 23
    		$-2.40$-2.00-20.00%Miss+35.1%
    Mar 23
    		$-1.50$-1.70+11.76%Beat+51.6%
    Dec 22
    		$-0.14$-0.19+26.32%Beat+60.0%
    Sep 22
    		$0.34N/A+134.00%Beat+107.2%
    Jun 22
    		$-3.70$-3.20-15.63%Miss+14.0%
    Mar 22
    		$-3.10$-4.47+30.65%Beat-675.0%
    Dec 21
    		$-0.35$-0.50+30.00%Beat+32.7%
    Sep 21
    		$-4.70$-5.10+7.84%Beat-11.9%
    Jun 21
    		$-4.30$-4.07-5.65%Miss-13.2%
    Mar 21
    		$-0.40N/A+88.34%Beat-2.6%
    Dec 20
    		$-0.52$-0.42-23.81%Miss+83.2%
    Sep 20
    		$-4.20$-4.33+3.00%Beat-75.0%
    Jun 20
    		$-3.80$-4.60+17.39%Beat-35.7%
    Mar 20
    		$-0.39$-0.38-2.63%Miss+87.0%
    Dec 19
    		$-3.10$-2.95-5.08%Miss-933.3%
    Sep 19
    		$-2.40$-2.70+11.11%Beat+11.1%
    Jun 19
    		$-2.80$-3.40+17.65%Beat+45.1%
    Mar 19
    		$-3.00$-2.85-5.26%Miss-3650.0%
    Dec 18
    		$-0.30$-0.27-11.11%Miss-66.7%
    Sep 18
    		$-2.70$-2.50-8.00%Miss-13400.0%
    Jun 18
    		$-5.10$-3.60-41.67%Miss-
    Mar 18
    		$-0.08$0.00N/AMiss-
    Dec 17
    		$-0.18$0.00N/AMiss-
    Mar 17
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.56EV/EBITDA-11.70x
    Price/FCF-8.72xFCF Yield-11.47%
    Profitability
    Profit Margin-102.80%Operating Margin-194.50%
    ROE-240.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-5.05x
    Current Ratio1.45xQuick Ratio1.33x
    Trading Statistics
    Beta1.49Avg Volume109.11K
    52-Week High$9.8252-Week Low$3.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.03
    SMA 20$5.09
    SMA 50$5.51
    SMA 200$6.23
    EMA 10$5.16
    EMA 20$5.16
    EMA 50$5.41
    EMA 200$5.84

    MACD

    Line: -0.06Signal: -0.16Hist: 0.09

    ADX

    ADX: 12.9+DI: 22.7-DI: 13.1

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down80.0
    PSAR$4.68

    Bollinger Bands

    Upper Band$5.63
    Lower Band$4.55
    %B Position2119%(Upper)
    Band Width0.84

    RSI (14-Day)

    Neutral
    55.4

    Momentum Oscillators

    Stoch %K64.6
    Stoch %D48.5
    Williams %R-32.0
    ROC (10d)11.7%
    Momentum0.57
    CCI (20d)123.0
    MFI (14d)67.0

    Volatility Measures

    ATR (14d)$0.46(8.4%)
    StdDev (20d)0.27
    Hist Vol66.6%(High)

    Volume Flow

    VWAP$5.53
    OBV8.8M
    AD Line6.5B
    CMF (20d)-0.203

    Volume Metrics

    Avg Vol (20d)113.0K
    Vol Ratio0.9x
    VWMA (20d)$5.14

    Pivot Points

    R3$6.89
    R2$6.38
    R1$6.03
    Pivot Point$5.52
    S1$5.17
    S2$4.66
    S3$4.31

    Advanced Oscillators

    TSI-5.97
    Ultimate Osc46.9
    KST-92.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.86M$5.02M$5.09M$14.34M$12.70M$3.44M$344,000$-1,781,000$5.18M$3.83M$1.99M$2.92M
    Cost of Revenue$435,000$544,000$675,000$754,000$340,000$423,000$596,000$351,000$360,000$546,000$144,000$145,000
    Gross Profit$5.43M$4.48M$4.42M$13.59M$12.36M$3.02M$-252,000$-2,132,000$4.82M$3.28M$1.84M$2.77M
    Operating Expenses$18.52M$14.19M$11.61M$11.96M$10.85M$11.15M$11.16M$18.57M$20.02M$21.88M$24.98M$26.69M
    R&D$6.03M$3.86M$2.52M$2.21M$1.85M$2.28M$1.17M$2.40M$3.32M$4.95M$5.32M$6.51M
    SG&A$10.35M$9.99M$8.12M$9.40M$8.85M$8.85M$9.88M$16.08M$16.52M$16.34M$17.00M$20.05M
    Operating Income$-13,097,000$-9,715,000$-7,192,000$1.63M$1.51M$-8,130,000$-11,410,000$-20,704,000$-15,206,000$-18,599,000$-23,137,000$-23,917,000
    Interest Income$111,000$201,000$205,000$159,000$228,000$337,000$205,000$221,000$393,000$598,000$792,000$822,000
    Interest Expense$164,000$160,000$2.85M$2.09M$2.13M$2.20M$2.35M$2.38M$2.37M$2.32M$2.31M$1.66M
    Income Before Tax$-13,153,000$-9,682,000$-8,074,000$-274,000$204,000$-9,742,000$-16,202,000$-22,860,000$-17,186,000$-20,331,000$-24,600,000$-24,802,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-13,153,000$-9,682,000$-8,074,000$-274,000$204,000$-9,742,000$-16,202,000$-22,860,000$-17,186,000$-20,331,000$-24,614,000$-24,802,000
    EBITDA$-12,893,000$-9,529,000$-5,242,000$1.84M$2.31M$-7,668,000$-13,805,000$-20,363,000$-14,877,000$-18,270,000$-22,870,000$-23,757,000
    EBIT$-13,100,000$-9,723,000$-5,432,000$1.66M$2.11M$-7,876,000$-14,058,000$-20,705,000$-15,211,000$-18,610,000$-23,087,000$-23,967,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VRCA

    News

    Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

    Analysts have issued a consensus "Hold" rating for Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), with an average 12-month price target significantly higher than its current trading price. Institutional investors and hedge funds hold a substantial portion of the company's stock, with many increasing their positions recently. Verrica Pharmaceuticals is a clinical-stage biopharmaceutical company focused on topical dermatological treatments, including its lead candidate VP-102.

    MarketBeat•8/20/26•
    Neutral

    Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

    Verrica Pharmaceuticals CEO Jayson Rieger recently purchased 5,000 shares of the company's stock for $24,550, increasing his total ownership to 207,593 shares. This transaction occurred as the stock fell 4.3% to $4.68, bringing its market capitalization to approximately $80.4 million. The company has mixed analyst sentiment, holding an average "Hold" rating with a target price of $14.50.

    MarketBeat•8/18/26•
    Neutral

    Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

    Verrica Pharmaceuticals' (NASDAQ:VRCA) Chief Marketing Officer, Noah Rosenberg, purchased 4,200 shares of the company's stock for $20,622, increasing his direct ownership by 178.19%. This transaction occurred as VRCA shares traded down, below their 50-day and 200-day moving averages. The company holds an $80.4 million market capitalization, with a mixed analyst consensus of "Hold" and a $14.50 price target.

    MarketBeat•8/18/26•
    Neutral

    VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges

    Verrica Pharmaceuticals Inc (NASDAQ: VRCA) saw its CEO purchase 25,000 shares, leading to a 7.5% after-hours price increase and renewed investor interest despite ongoing profitability challenges. While the GF Value™ suggests VRCA is 50.3% undervalued, this should be viewed cautiously given the company's negative earnings and weak financial strength. Insider buying activity remains a key positive signal, contrasting with some institutional caution.

    GuruFocus•8/18/26•
    Somewhat-Bullish

    Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August

    Verrica Pharmaceuticals Inc. (VRCA) CEO Jayson Rieger purchased 25,000 shares of common stock in August 2026. These open-market transactions included 5,000 shares bought on August 17 at $4.91 per share and 20,000 shares on August 14 at a weighted average price of $5.06. The filing also notes indirect holdings through a child and family trusts, for which Rieger disclaims beneficial ownership.

    Stock Titan•8/18/26•
    Bullish

    Frequently Asked Questions About VRCA

    Does VRCA pay dividends?
    Verrica Pharmaceuticals Inc (VRCA) does not currently pay a regular dividend.
    What is VRCA's market cap?
    Verrica Pharmaceuticals Inc (VRCA) has a market capitalization of $97.75M with a current stock price of $5.46.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In